» Authors » Philip Thompson

Philip Thompson

Explore the profile of Philip Thompson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 2174
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Rahimi M, Corlett A, Van Zuylekom J, Sani M, Blyth B, Thompson P, et al.
Theranostics . 2024 Mar; 14(5):1815-1828. PMID: 38505611
Peptides are ideal for theranostic development as they afford rapid target accumulation, fast clearance from background tissue, and exhibit good tissue penetration. Previously, we developed a novel series of peptides...
2.
Wang X, Patil N, Li F, Wang Z, Zhan H, Schmidt D, et al.
Comput Biol Med . 2023 Nov; 168:107681. PMID: 37992470
The multidrug-resistant Gram-negative bacteria has evolved into a worldwide threat to human health; over recent decades, polymyxins have re-emerged in clinical practice due to their high activity against multidrug-resistant bacteria....
3.
Pan B, Weerasinghe H, Sezmis A, McDonald M, Traven A, Thompson P, et al.
ACS Infect Dis . 2023 Sep; 9(10):1901-1917. PMID: 37756147
Fungal infections pose a significant and increasing threat to human health, but the current arsenal of antifungal drugs is inadequate. We screened the Medicines for Malaria Venture (MMV) Pathogen Box...
4.
Menon A, Subasic de Azevedo I, Choong K, Bhatnagar D, Wang C, Sluka P, et al.
Cardiovasc Eng Technol . 2023 May; 14(4):605-614. PMID: 37165253
Purpose: The Lumi-Solve photo-angioplasty drug eluting balloon catheter (DEBc) may afford safety advantages over current DEBc. Lumi-Solve utilises the guidewire (GW) port and lumen to deliver fibre-optic UV365nm light to...
5.
Bazinet A, Kadia T, Short N, Borthakur G, Wang S, Wang W, et al.
Blood Adv . 2023 Mar; 7(13):3284-3296. PMID: 36884300
Acute myeloid leukemia (AML) can be treated with either high- or low-intensity regimens. Highly sensitive assays for measurable residual disease (MRD) now allow for a more precise assessment of response...
6.
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, et al.
Blood Adv . 2022 Oct; 7(10):1958-1966. PMID: 36287248
Richter transformation (RT) is a rare complication of chronic lymphocytic leukemia (CLL) that has dismal outcomes. Upregulation of PD-1/PD-L1 drives immunological evasion in patients with RT. We hypothesized that combining...
7.
Jabbour E, Sasaki K, Haddad F, Issa G, Skinner J, Dellasala S, et al.
Am J Hematol . 2022 Sep; 97(11):1413-1418. PMID: 36054032
Low-dose dasatinib is safe and effective in patients with chronic myeloid leukemia in chronic phase (CML-CP). No randomized trials have compared the outcome with standard-dose dasatinib. This study aims to...
8.
Cherng H, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, et al.
Am J Hematol . 2022 May; 97(8):1005-1012. PMID: 35567779
Long-term follow up of prospective studies has shown that continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy leads to durable remissions in previously untreated patients with TP53-altered chronic lymphocytic leukemia (CLL);...
9.
Jelloul F, Yang R, Garces S, Kanagal-Shamanna R, Ok C, Loghavi S, et al.
Leuk Res . 2022 Apr; 116:106827. PMID: 35430388
NOTCH1 is one of the most frequently mutated genes in chronic lymphocytic leukemia and has emerged as a marker of poor prognosis. In addition to coding NOTCH1 mutations involving exon...
10.
Griffen T, Hoff F, Qiu Y, Lillard Jr J, Ferrajoli A, Thompson P, et al.
Blood Cancer J . 2022 Mar; 12(3):43. PMID: 35301276
Protein expression for 384 total and post-translationally modified proteins was assessed in 871 CLL and MSBL patients and was integrated with clinical data to identify strategies for improving diagnostics and...